MAGE-TAB Version 1.1
Comment[MetaboBank accession] MTBKS281
Study Title Metabolomic analysis of lipt2 mutants in drosophila melanogaster
Study Description Metabolite profiling using LC-QTOF-MS revealed distinct metabolic disruptions in lipt2 mutants.
Experimental Design genotype design
Experimental Factor Name genotype
Experimental Factor Type genotype
Person Last Name Kishita
Person First Name Yoshihito
Person Mid Initials
Person Affiliation Graduate School of Medicine, Juntendo University
Person Roles submitter
PubMed ID
Publication DOI
Protocol Name Sample collection Extraction Chromatography Mass spectrometry Data processing Metabolite identification
Protocol Type Sample collection Extraction Chromatography Mass spectrometry Data processing Metabolite identification
Protocol Description Flies were maintained at 25°C on standard glucose-yeast-agar medium supplemented with 0.1% propionic acid and 0.01% n-butyl p-hydroxybenzoate as mold inhibitors. w1118 was used as a control. Flies heterozygous for PBacCG9804e00304 (lipT21) and PBacCG9804e00304 (lipT21) were used as a lipT2 loss-of-function mutant to minimize the effects of potential background mutations derived from each stock.Metabolomic analyses were performed using 7-day-old adult male flies prior to severe terminal decline. Ten adult flies were homogenized in either acetonitrile/water (3:1) or distilled water contained 25μM L-Phenylalanine-13C9,15N on ice. Whereas homogenate in acetonitrile/water was centrifuged to remove debris, homogenate in water was added to 3 volume of acetonitrile and then centrifuged. The supernatant was dried up using miVac Sample Concentrator (Genevac) and dissolved in 20μl of distilled water. The contents of individual compound in the sample were measured by waters liquid chromatography quadropole time-of-flight mass spectrometry system (LC: Acquity UPLC, MS: Xevo QTofMS). Solvent A and B were 10 mM Dibutyl ammonium acetate (pH4.95) and s methanol in HPLC grade, respectively. A flow rate was 0.35 ml/min and 5μl of sample was injected. The gradient elution was as follows: 0-1.5 min 0% B, 1.5-5.0 min linear from 0% to 12% B, 5.0-10.0 min linear from 12% to 30% B, 10.0-13.0 min linear from 30% to 55% B, 13.0-14.0 min linear from 55% to 98% B,and 14.0-16.0 min from 98% B, with 16.0-16.1 min for initial conditions of 0% B for column equilibration. Chromatographic separation was performed at 45°C using an ACQUITY UPLC HSS T3 Column (1.0 x 100 mm, 1.8 µm; Waters). The contents of individual compound in the sample were measured by waters liquid chromatography quadropole time-of-flight mass spectrometry system (LC: Acquity UPLC, MS: Xevo QTofMS). MS system equipped with a dual electrospray ionization (ESI) probe and operated in the negative ion mode and source temperature was 120 °C The mass scanning range was m/z50-1000. Mass measurement was calibrated by lock masses to obtain high mass accuracy of analysis. Leucine enkephalin ([M-H]- = 554.2620) was used as a lock mass. Obtained ion intensity of each compound was normalized against ion intensity of L-Phenylalanine-13C9,15N. Data not submitted. Data not submitted.
Protocol Parameters Post extraction;Derivatization Chromatography instrument;Autosampler model;Column model;Column type;Temperature;Guard column Scan polarity;Scan m/z range;Instrument;Ion source;Mass analyzer
Protocol Hardware
Protocol Software
Public Release Date 2026-06-05
Term Source Name
Term Source File
Term Source Version
SDRF File MTBKS281.sdrf.txt
Comment[Study type] metabolic profiling
Comment[Experiment type] liquid chromatography-mass spectrometry
Comment[Submission type] LC-MS
Comment[BioProject] PRJDB42279
Comment[Related study]
Comment[Contributor]
Comment[Submission Date] 2026-05-26
Comment[Last Update Date] 2026-06-05